Combination chemotherapy with docetaxel and cisplatin in weekly schedule in the treatment of 30 cases of advanced non-small cell lung cancer
- VernacularTitle:多西紫杉醇联合顺铂每周给药治疗Ⅲ～Ⅳ期NSCLC 30例
- Author:
Yu ZHANG
1
;
Like YU
;
Wenping CHEN
Author Information
1. Nanjin Chest Hospital Nanjin
- From:
Chinese Journal of Lung Cancer
2001;4(3):197-199
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the response rate, survival time and toxicity of docetaxel and cisplatin in weekly schedule in the treament of stage Ⅲ-Ⅳ non-small cell lung cancer. Methods A total of 30 cases of stage Ⅲ-Ⅳ non-small cell lung cancer was included in this study. Docetaxel 25*!mg／m2 and cisplatin 25*!mg／m2 were given through intravenous dripping for the 1st, 8th, and 15th days. The chemotherapy was repeated every 28 days. Each patient was given at least 2 cycles. Results The overall response rate was 43.3％ (13／30，all were partial response). Quality of life of the patients was improved (there were 66.7％ of the patients with Karnofsky score increased or unchanged). Median remission duration was 7 months. 40％ of the patients survived for more than 1 year. The main toxicity was hematological: Grade Ⅲ-Ⅳ leucopenia was 16.7％; Grade Ⅲ thrombocytopenia was 6.7％. The non-hematological toxicity was mild. Conclusion The regimen of docetaxel and cisplatin in weekly schedule is effective and tolerable in the treatment of non-small cell lung cancer.
